专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012122513A2 GENERATION OF ANTI-FN14 MONOCLONAL ANTIBODIES BY EX-VIVO ACCELERATED ANTIBODY EVOLUTION 审中-公开
标题翻译：抗-IFN14单克隆抗体的生成通过加速抗体进化
公开(公告)号：WO2012122513A2
公开(公告)日：2012-09-13
申请号：PCT/US2012/028584
申请日：2012-03-09
申请人： OMEROS CORPORATION , LEPPARD, John, Benjamin , WOOD, Christi, L. , CUMMINGS, W., Jason , YABUKI, Munehisa , MAIZELS, Nancy , ALLISON, Daniel, S. , TJOELKER, Larry, W.
发明人： LEPPARD, John, Benjamin , WOOD, Christi, L. , CUMMINGS, W., Jason , YABUKI, Munehisa , MAIZELS, Nancy , ALLISON, Daniel, S. , TJOELKER, Larry, W.
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/30 , C07K16/2878 , C07K2317/14 , C07K2317/23 , C07K2317/24 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/77 , C07K2317/92 , C07K2319/55
摘要： The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
摘要翻译：本发明一般涉及抗FN14抗体。特别地，本文所述的抗FN14抗体可用于治疗与FN14表达相关的疾病，例如多种癌症。

2. 发明申请

WO2013025446A2 ANTI-FZD10 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE 审中-公开
标题翻译： ANTI-FZD10单克隆抗体及其使用方法
公开(公告)号：WO2013025446A2
公开(公告)日：2013-02-21
申请号：PCT/US2012/050177
申请日：2012-08-09
申请人： OMEROS CORPORATION , CUMMINGS, W., Jason , YABUKI, Munehisa , LEPPARD, John, Benjamin , WOOD, Christi, L. , MAIZELS, Nancy , ALLISON, Daniel, S. , TJOELKER, Larry, W.
发明人： CUMMINGS, W., Jason , YABUKI, Munehisa , LEPPARD, John, Benjamin , WOOD, Christi, L. , MAIZELS, Nancy , ALLISON, Daniel, S. , TJOELKER, Larry, W.
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2896 , A61K39/39558 , A61K45/06 , A61K47/6825 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K16/28 , C07K16/2863 , C07K16/30 , C07K2317/23 , C07K2317/24 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.
摘要翻译：本发明一般涉及抗FZD10抗体以及使用抗FZD10抗体的方法。特别地，本文所述的抗FZD10抗体可用于改变胚胎干细胞的存活，复制，分化和上皮 - 间充质细胞转化中的一种或多种，和/或用于治疗疾病如多种癌症，与FZD10的表达相关，包括作为独立治疗和与其他药物的联合治疗。

3. 发明申请

WO2018026722A1 COMPOSITIONS AND METHODS OF INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS 审中-公开
标题翻译：抑制MASP-3治疗各种疾病和病症的组合物和方法
公开(公告)号：WO2018026722A1
公开(公告)日：2018-02-08
申请号：PCT/US2017/044714
申请日：2017-07-31
申请人： OMEROS CORPORATION , UNIVERSITY OF LEICESTER , CUMMINGS, W., Jason , DEMOPULOS, Gregory, A. , DUDLER, Thomas , SCHWAEBLE, Hans-Wilhelm , TJOELKER, Larry, W. , WOOD, Christi, L. , YABUKI, Munehisa
发明人： CUMMINGS, W., Jason , DEMOPULOS, Gregory, A. , DUDLER, Thomas , SCHWAEBLE, Hans-Wilhelm , TJOELKER, Larry, W. , WOOD, Christi, L. , YABUKI, Munehisa
IPC分类号： A61K39/395 , A61K45/06 , C07K16/40
摘要： The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
摘要翻译：本发明涉及MASP-3抑制性抗体和包含此类抗体的组合物，其用于抑制MASP-3依赖性补体活化的不利影响。

4. 发明申请

WO2006110593A2 BIOLOGICAL TARGETS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER 审中-公开
标题翻译：用于诊断，治疗和预防癌症的生物学目标
公开(公告)号：WO2006110593A2
公开(公告)日：2006-10-19
申请号：PCT/US2006/013172
申请日：2006-04-07
申请人： MACROGENICS, INC. , VON HALLER, Priska, D. , SCHUMMER, Michèl , MEYER, David, W. , SCHUBERT, Lisa, A. , TJOELKER, Larry, W.
发明人： VON HALLER, Priska, D. , SCHUMMER, Michèl , MEYER, David, W. , SCHUBERT, Lisa, A. , TJOELKER, Larry, W.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158
摘要： The present invention relates to methods for detecting, diagnosing, monitoring and prognosing cancer by detecting differences in the expression of one or more, or any combination of the following genes: SLC12A2, FLJ23375, GRM5, TAS2R1, NRXN2, C14orfl60, MGC15668, MGC33486, TMEM16F, FAT, KIAA0195, LRFN, NFASC, BAT2D1, MGC2963, KIAA0685, EDG3, GGTL3, PLVAP, FLJ31528, FLJ90709, VEZATIN, TMPRSS9, ATP13A5, PKHDlLl, C2orfl8, ANKRD22, FAM62B, LOC57168, CDKALl, SLC39A3vl, SLC39A3v2, BAT5, TM9SF4, DC2, VAPB, XTP3TPB, TACSTD2, FNDC3A, GKOOl, OCIAD2, PRO1855, C20orf3, SDFRl, FLJ20481, LENG4, FLJ12443, ARP5 Long, ARP5 Short, TMD0645, NGEP, ILlRAPl, PLXNBl, ATP2B2, FLJl 1848, ENTPD2, PPMlH, KRTKAP3, KCNC3, TM9SF1, ULBPl, C19orf26, KIAA830, KIAA1244, KIAA1797, MGC26856, NETO2, SUSD2, FOLR2, EMR2, ENTPDl, ATPlOB, PTK7, FLJ14681, C20orf22, FLJ14281, FAM8A1, TMED7, C20orfl08, ATADl, GPR154, C14orf27, OSAP, FAD104, FLJ90492, SLC27A3, RON, ATP13A1, DKFZP564D166, ESSPL, EXTL3, KAIl, KIAA0960, MTRNL, SLC27A1, GRIA4, 0R4M1, KIAA1679 or UPK-Ib. The present invention also relates to methods for screening and identifying compounds that modulate the expression of one or more, or any combination of such genes. The invention further relates to the use of such compounds in the prevention, treatment, management and amelioration of cancer. The methods of the invention also comprise the administration of an effective amount of one or more therapies that modulate the expression and/or activity of one or more cancer targets disclosed herein for the prevention, treatment, management and amelioration of cancer.
摘要翻译：本发明涉及检测，诊断，监测和预测癌症的方法，该方法通过检测以下基因中的一种或多种或任何组合的表达差异：SLC12A2，FLJ23375，GRM5，TAS2R1，NRXN2，C14orfl60，MGC15668，MGC33486， TMEM16F，FAT，KIAA0195，LRFN，NFASC，BAT2D1，MGC2963，KIAA0685，EDG3，GGTL3，PLVAP，FLJ31528，FLJ90709，VEZATIN，TMPRSS9，ATP13A5，PKHD1L1，C2orf18，ANKRD22，FAM62B，LOC57168，CDKAL1，SLC39A3v1，SLC39A3v2，BAT5， TM9SF4，DC2，VAPB，XTP3TPB，TACSTD2，FNDC3A，GK001，OCIAD2，PRO1855，C20orf3，SDFR1，FLJ20481，LENG4，FLJ12443，ARP5 Long，ARP5 Short，TMD0645，NGEP，IL1RAP1，PLXNB1，ATP2B2，FLJ1848，ENTPD2，PPM1H ，KRTKAP3，KCNC3，TM9SF1，ULBP1，C19orf26，KIAA830，KIAA1244，KIAA1797，MGC26856，NETO2，SUSD2，FOLR2，EMR2，ENTPD1，ATP10B，PTK7，FLJ14681，C20orf22，FLJ14281，FAM8A1，TMED7，C20orfl08，ATAD1，GPR154，C14orf27 ，OSAP，FAD104，FLJ90492，SLC27A3，RON，ATP13A1，DKFZP564D166，ESSPL，EXTL3，KAI1，KIAA0960，MTRNL，SLC27 A1，GRIA4,0R4M1，KIAA1679或UPK-Ib。本发明还涉及筛选和鉴定调节这些基因的一种或多种或任何组合的表达的化合物的方法。本发明还涉及这些化合物在预防，治疗，治疗和改善癌症中的用途。本发明的方法还包括施用有效量的一种或多种治疗剂，其调节本文公开的一种或多种癌症靶标的表达和/或活性以预防，治疗，治疗和改善癌症。

5. 发明申请

WO2011031833A2 HUMAN ANTI-CANCER ANTIBODIES 审中-公开
标题翻译：人类抗癌抗体
公开(公告)号：WO2011031833A2
公开(公告)日：2011-03-17
申请号：PCT/US2010/048234
申请日：2010-09-09
申请人： THERACLONE SCIENCES, INC. , HAMMOND, Phillip, W. , VAN DER VUURST DE VRIES, Anne-Renee , TJOELKER, Larry, W. , MOYLE, Matthew
发明人： HAMMOND, Phillip, W. , VAN DER VUURST DE VRIES, Anne-Renee , TJOELKER, Larry, W. , MOYLE, Matthew
IPC分类号： C07K16/30 , A61K39/395 , A61P35/00 , G01N33/574
CPC分类号： G01N33/57407 , C07K16/3015 , C07K16/3069 , C07K2317/515 , C07K2317/732 , C07K2317/92
摘要： The present invention provides novel human anti-cancer antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of cancer.
摘要翻译：本发明提供了新的人类抗癌抗体及相关组合物和方法。这些抗体用于癌症的诊断和治疗。

6. 发明申请

WO2013138518A1 COMPOSITION AND METHOD FOR DIVERSIFICATION OF TARGET SEQUENCES 审中-公开
标题翻译：用于目标序列多样化的组合物和方法
公开(公告)号：WO2013138518A1
公开(公告)日：2013-09-19
申请号：PCT/US2013/031036
申请日：2013-03-13
申请人： OMEROS CORPORATION , UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
发明人： CUMMINGS, W., Jason , TJOELKER, Larry, W. , WOOD, Christi, L. , YABUKI, Munehisa , ALLISON, Daniel, S. , LEPPARD, John, B. , MAIZELS, Nancy
IPC分类号： C12N15/63 , C12N15/13 , C12N15/70 , C12N15/79
CPC分类号： C12N15/1082 , C07K16/00 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/92
摘要： The disclosure relates generally to the targeting of genes to, and their integration into, an innnnunoglobulin (antibody) heavy chain locus. In particular, the methods described herein contemplate replacing the single rearranged heavy chain V, D, and J genes of a B cell lymphoma such as DT40 with independently rearranged V H -D-J H genes of chicken, in a system for generating immunoglobulin diversity. Also contemplated is replacement of the chicken V H -D-J H with rearranged V H -D-J H genes of other vertebrates including human in a system for generating immunoglobulin diversity, with the exception of any substitution disclosed and claimed in PCT application WO 2009/029315 A2. Regions upstream of the rearranged V H gene, and downstream of the rearranged J H genes, are identified and incorporated into the immunoglobulin heavy chain gene-targeting vectors for efficient gene replacement. Also described is construction of a diverse chicken immunoglobulin heavy chain VDJ library in DT40 by homologous gene replacement of the single endogenous rearranged VDJ gene with a chicken VDJ repertoire using the described targeting vectors. The methods are useful for generating a diverse library of immunoglobulins that can be screened for binding to desired target antigens. Compositions include the unique targeting vectors, the diverse chicken heavy chain VDJ library in the targeting vectors, and the diverse chicken VDJ DT40 library that is created by homologous gene replacement of the single endogenous rearranged VDJ gene with a chicken VDJ repertoire, using the targeting vectors.
摘要翻译：本公开一般涉及将基因靶向于其和无融合蛋白（抗体）重链基因座的融合体。特别地，本文描述的方法考虑在用于产生免疫球蛋白多样性的系统中将具有独立重排的鸡的VH-D-JH基因的B细胞淋巴瘤（例如DT40）的单重排列重链V，D和J基因替换为鸡的VH-D-JH基因。还考虑到，除了在PCT申请WO 2009/029315A2中公开和要求保护的任何替代物之外，在用于产生免疫球蛋白多样性的系统中替换包括人在内的其它脊椎动物的重排的VH-D-JH基因的鸡VH-D-JH 。鉴定重新排列的VH基因上游区域和重新排列的JH基因的下游区域，并将其并入免疫球蛋白重链基因靶向载体中以进行有效的基因替换。还描述了使用所述靶向载体通过用单独的内源重排的VDJ基因与鸡VDJ库的同源基因替换来构建DT40中的多种鸡免疫球蛋白重链VDJ文库。该方法可用于产生可筛选以结合所需靶抗原的免疫球蛋白的多样化文库。组合物包括独特的靶向载体，靶向载体中不同的鸡重链VDJ文库，以及通过使用靶向载体的单个内源重排的VDJ基因的同源基因替换产生的多样化的鸡VDJ DT40文库。

7. 发明申请

WO2018026722A8 COMPOSITIONS AND METHODS OF INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS 审中-公开
公开(公告)号：WO2018026722A8
公开(公告)日：2018-02-08
申请号：PCT/US2017/044714
申请日：2017-07-31
申请人： OMEROS CORPORATION , UNIVERSITY OF LEICESTER
发明人： CUMMINGS, W., Jason , DEMOPULOS, Gregory, A. , DUDLER, Thomas , SCHWAEBLE, Hans-Wilhelm , TJOELKER, Larry, W. , WOOD, Christi, L. , YABUKI, Munehisa
IPC分类号： A61K39/395 , A61K45/06 , C07K16/40
摘要： The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

8. 发明申请

WO2014144542A2 METHODS OF GENERATING BIOACTIVE PEPTIDE-BEARING ANTIBODIES AND COMPOSITIONS COMPRISING THE SAME 审中-公开
标题翻译：生成含有活性肽的抗体的方法和包含该抗体的组合物
公开(公告)号：WO2014144542A2
公开(公告)日：2014-09-18
申请号：PCT/US2014/028999
申请日：2014-03-14
申请人： OMEROS CORPORATION
发明人： CUMMINGS, W., Jason , GRAY, Patrick , TJOELKER, Larry, W. , YABUKI, Munehisa
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , A61K2039/505 , C07K14/811 , C07K16/00 , C07K2317/21 , C07K2317/23 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2318/10 , C07K2319/00 , C07K2319/30
摘要： In one aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, comprising a bioactive peptide amino acid sequence, wherein the bioactive peptide amino acid sequence is an inhibitor of the complement system and is fused to at least one of: (i) the amino terminal region of at least one of: a light chain variable region and/or a heavy chain variable region; or (ii) the carboxy terminal region of at least one of: a light chain constant region and/or a heavy chain constant region, wherein the antibody inhibits complement activation.
摘要翻译：
在一个方面，本发明提供分离的抗体，或其抗原结合片段，其包含生物活性肽的氨基酸序列，其中所述生物活性肽的氨基酸序列是补体系统的抑制剂和是与以下至少一个融合：（i）轻链可变区和/或重链可变区中的至少一个的氨基末端区; 或（ii）轻链恒定区和/或重链恒定区中的至少一个的羧基末端区，其中所述抗体抑制补体活化。

9. 发明公开

EP2968546A2 METHODS OF GENERATING BIOACTIVE PEPTIDE-BEARING ANTIBODIES AND COMPOSITIONS COMPRISING THE SAME 有权
标题翻译：生成含有活性肽的抗体的方法和包含该抗体的组合物
公开(公告)号：EP2968546A2
公开(公告)日：2016-01-20
申请号：EP14764165.8
申请日：2014-03-14
申请人： Omeros Corporation
发明人： CUMMINGS, W., Jason , GRAY, Patrick , TJOELKER, Larry, W. , YABUKI, Munehisa
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , A61K2039/505 , C07K14/811 , C07K16/00 , C07K2317/21 , C07K2317/23 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2318/10 , C07K2319/00 , C07K2319/30
摘要： In one aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, comprising a bioactive peptide amino acid sequence, wherein the bioactive peptide amino acid sequence is an inhibitor of the complement system and is fused to at least one of: (i) the amino terminal region of at least one of: a light chain variable region and/or a heavy chain variable region; or (ii) the carboxy terminal region of at least one of: a light chain constant region and/or a heavy chain constant region, wherein the antibody inhibits complement activation.
摘要翻译：一方面，本发明提供了包含生物活性肽氨基酸序列的分离的抗体或其抗原结合片段，其中所述生物活性肽氨基酸序列是补体系统的抑制剂并且融合至以下至少一种： i）至少以下之一的氨基末端区：轻链可变区和/或重链可变区; 或（ii）轻链恒定区和/或重链恒定区中的至少一个的羧基末端区，其中所述抗体抑制补体激活。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式